This is a preview of subscription content, log in via an institution to check access.
Notes
2018 US dollars
Reference
Zeng X, et al. Economic Evaluation of Adding Daratumumab to a Regimen of Bortezomib + Dexamethasone in Relapsed or Refractory Multiple Myeloma: Based on the Latest Updated Analysis of CASTOR. Clinical Therapeutics : 20 Jan 2020. Available from: URL: http://doi.org/10.1016/j.clinthera.2019.12.007
Rights and permissions
About this article
Cite this article
Add-on daratumumab not cost effective in RRMM. PharmacoEcon Outcomes News 846, 4 (2020). https://doi.org/10.1007/s40274-020-6543-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6543-9